Compare AbCellera Biologics Inc (ABCL) vs Salesforce Inc (CRM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Salesforce Inc — how do they compare? AbCellera Biologics Inc trades at $7.22 (market cap $2.35B), while Salesforce Inc trades at $166.36 (market cap $138.84B). The key difference: Salesforce Inc is far larger — about 59.1× AbCellera Biologics Inc's market cap, and Salesforce Inc pays a 1.04% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | CRM | |
|---|---|---|
Market Cap | $2.35B | $138.84B |
Sector | Health | Technology |
52-Week High | $8.12 | $273.65 |
52-Week Low | $2.78 | $150.12 |
Enterprise Value | $1.99B | $168.88B |
Dividend Yield | — | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Salesforce (CRM) trades at $166.59, up 0.57% today, with strong fundamentals including 77.64% gross margins and consistent earnings beats. The stock faces technical headwinds with mixed signals from moving averages and oscillators, while analyst consensus remains strongly bullish with a $235.20 price target. Recent news highlights AI-driven growth potential amid sector volatility.
Outlook: CRM's robust profitability and AI monetization (Agentforce ARR up 200% YoY per Seeking Alpha Apr 3) support upside, but near-term risks include software sector sell-offs and RSI overbought conditions. Valuation at 19.64 P/E offers room for growth if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →
